Use of angiotensin-converting enzyme inhibitors or receptor blockers is associated with reduced mortality in patients with post-acute kidney injury: meta-analysis
H. Shi, Q. Peng, X.-L. Zhou, S.-P. Zhu, S.-Y. Sun Department of Traditional Chinese Medicine, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, Guangdong Province, China. shengyunsun2020@163.com
OBJECTIVE: To investigate the association between the use of ACEis or ARBs and outcomes in patients recovering from AKI.
MATERIALS AND METHODS: We searched PubMed, MEDLINE, Cochrane Database, Web of Science and Embase databases from inception to May 2021 and performed a systematic review and meta-analysis using the “meta” package in R 4.0.3.
RESULTS: Five cohort studies, published from 2018 to 2021 with 153174 participants and approximately 39081 mortalities, were included in our meta-analysis. The meta-analysis showed that the use of ACEis/ARBs in patients with post-AKI is associated with a significantly lower risk of death (HR 0.80; 95% CIs, 0.72-0.90) and subgroup analysis showed a significant result in ACEi/ARB users with over 1-year of follow-up (HR 0.86; 95% CIs, 0.77-0.95).
CONCLUSIONS: The use of ACEi/ARB in patients with post-AKI is associated with a significantly lower risk of death.
Free PDF Download
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
H. Shi, Q. Peng, X.-L. Zhou, S.-P. Zhu, S.-Y. Sun
Use of angiotensin-converting enzyme inhibitors or receptor blockers is associated with reduced mortality in patients with post-acute kidney injury: meta-analysis
Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 15
Pages: 4900-4908
DOI: 10.26355/eurrev_202108_26447